MS RESEARCH AUSTRALIA BRAIN BANK NEWS
Pharmaceutical company Sanofi have advised that their MS disease modifying therapy Aubagio will be delisted from the Australian market from October 2021.
Australian researchers and disease-based charities are working together to promote and simplify access to evidence-based stem cell therapies in Australia.
Genes affect the risk of developing MS, but what about MS relapses? Two new studies uncover clues to MS biology hidden in our genetic code.
MS Research Australia is currently funding 62 research projects covering a range of MS research priorities, including causes and prevention, better treatments and reversal of disability through repair or regeneration of cells.
The International Progressive MS Alliance has just announced the recipients of this year’s Research Challenge awards, that will channel €1,425,000 (AUD $ 2,249,000) into identifying new therapeutic targets in progressive MS.
Mayzent (siponimod) the first MS medication approved for secondary progessive MS in Australia, has been listed on the Pharmaceutical Benefits Scheme (PBS).
Two MS Research Australia funded research groups are investigating the role of messenger molecules and uncovering how genes increase the risk of ms.
New research from the International Progressive MS Alliance discovers a way nerve fibres protect themselves from damage.